Post-surgery treatment for high-risk early-stage lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests different targeted therapies after surgery to lower the risk of early-stage lung cancer returning. It's designed for patients with high-risk features, and the treatment depends on the genetic changes in the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You had surgery to completely remove your early-stage (IA or IB) non-small cell lung cancer (a common type of lung cancer).
- Your cancer shows at least one high-risk feature, like being less differentiated or having certain growth patterns.
- Tests must have confirmed whether your cancer has an EGFR mutation, ALK or ROS1 gene change, or none of these.
- You should be in good overall health (able to do daily activities) and not have other serious medical conditions.
- Your surgery must have been 4 to 10 weeks ago, and you must be fully recovered.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how well a targeted medicine (icotinib) combined with chemotherapy works before surgery for certain EGFR-mutated lung adenocarcinoma. The goal is to shrink or control the tumor and make surgery more effective.
This trial tests if a targeted therapy pill (befotertinib) can lower the chance of cancer coming back after surgery for non-small cell lung cancer that has a specific EGFR mutation. You may be eligible if your tumor was completely removed and you have stage IB to IIIB disease.
This trial tests a combination of radiation therapy before surgery, followed by the immunotherapy drug tislelizumab and the targeted therapy drug anlotinib after surgery, for people with stage II to IIIA non-small cell lung cancer (NSCLC). The goal is to see if this approach can improve outcomes for patients whose tumors can be removed surgically.
This trial compares two treatments after lung cancer surgery: a new targeted drug (ensartinib) versus standard chemotherapy. The goal is to see if the targeted drug helps prevent the cancer from coming back.
This trial studies whether giving different cancer medicines before (and sometimes after) surgery improves outcomes for people with early-stage, operable lung cancer that has certain tumor markers. It may help by trying to shrink or control the cancer early and lower the chance it comes back.
This trial tests two drugs, benmelstobart (immunotherapy) and anlotinib (a targeted therapy), alone or combined, before surgery for non-small cell lung cancer. The goal is to see if these drugs shrink the tumor enough to improve the chances of a complete response after surgery.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.